Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib + abiraterone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Ipatasertib + abiraterone** is an investigational drug combination composed of ipatasertib, a selective ATP-competitive inhibitor of AKT (protein kinase B), and abiraterone acetate, an androgen biosynthesis inhibitor targeting CYP17A1. This combination is being developed primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients with PTEN-loss or activation of the PI3K/AKT pathway. The mechanism of action targets dual blockade of androgen receptor signaling (abiraterone) and the PI3K/AKT pathway (ipatasertib), which are both implicated in prostate cancer progression and treatment resistance. The combination has shown increased progression-free survival in patients whose tumors exhibit PTEN loss or related pathway activation, and is generally administered with prednisone/prednisolone. The combination is not currently approved for clinical use.
- Other names
- ipatasertib and abirateroneabiraterone acetate + ipatasertib
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)AR (Adrenergic receptors)
Beyond the preview
Go deeper on ipatasertib + abiraterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib + abiraterone.